Alitretinonin: A comprehensive review

Expert Opinion on Investigational Drugs

Volumn 17, Issue 3, 2008, Pages 437-443

  Cheng, Caleb ^a   Michaels, Jason ^b   Scheinfeld, Noah ^c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

9 cis retinoic acid; Alitretinoin; Chronic hand dermatitis; Kaposis' sarcoma; Retinoids

Indexed keywords

ALITRETINOIN; DIETHYLTOLUAMIDE; PLACEBO; RETINOIC ACID; TAZAROTENE; ANTINEOPLASTIC AGENT; RETINOIC ACID RECEPTOR;

ALOPECIA; APPLICATION SITE IRRITATION; BURNING SENSATION; CHEILITIS; CHRONIC HAND DERMATITIS; CLINICAL TRIAL; CONJUNCTIVITIS; DERMATITIS; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; EDEMA; ERYTHEMA; EXFOLIATIVE DERMATITIS; FLUSHING; FOOD AND DRUG ADMINISTRATION; HAND ECZEMA; HEADACHE; HUMAN; HYPERLIPIDEMIA; KAPOSI SARCOMA; LIP DISEASE; NONHUMAN; NUMMULAR DERMATITIS; OUTCOME ASSESSMENT; PALMOPLANTAR KERATODERMA; PARESTHESIA; PHOTOAGING; POMPHOLYX; PRURITUS; REVIEW; SIDE EFFECT; SKIN DEFECT; TREATMENT DURATION; TREATMENT RESPONSE; XEROSIS; XEROSTOMIA; HAND DISEASE; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; HAND DERMATOSES; HUMANS; RECEPTORS, RETINOIC ACID; SARCOMA, KAPOSI; TRETINOIN;

EID: 40949163385     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.17.3.437     Document Type: Review

References (27)

1. Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LX. Retinoic acid receptors. Pharmacol Rev 2006;58:712-25
2. Germain P, Chambon P, Eichele G, et al. International Union of Pharmacology. LXIII Retinoid X receptors Pharmacol Rev 2006;58:760-72
3. Wolf G. Is 9-cis-retinoic acid the endogenous ligand for the retinoic acid-X receptor? Nutr Rev 2006;64:532-8
4. Sakuta T, Kanayama T. Marked improvement induced in photoaged skin of hairless mouse by ER36009, a novel RARgamma-specific retinoid, but not by ER35794, an RXR-selective agonist. Int J Dermatol 2006;45:1288-95
5. Gillespie RF, Gudas LJ. Retinoid regulated association of transcriptional co-regulators and the polycomb group protein SUZ12 with the retinoic acid response elements of Hoxa1, RARbeta(2), and Cyp26A1 in F9 embryonal carcinoma cells. J Mol Biol 2007;372:298-316
6. Li M, Indra AK, Warot X, et al. Skin abnormalities generated by temporally controlled RXRalpha mutations in mouse epidermis. Nature 2000;407:633-6
7. Jensen T, Sorensen S, Solvsten H, et al. The vitamin D3 receptor and retinoid X receptors in psoriatic skin: the receptor levels correlate with the receptor binding to DNA. Br J Dermatol 1998; 138:225-8
8. DiPiro JT, Talbert RL, Yee GC, et al. Pharmacotherapy: A Pathophysiologic Approach, 6th edition. New York: McGraw-Hill; 2005
9. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th edition. New York. McGraw-Hill; 2006
10. Cheer SM, Foster RH. Alitretinoin. Am J Clin Dermatol 2000;1:307-14
11. Bollag W, Ott F. Successful treatment of chronic hand eczema with oral 9-cis-retinoic acid. Dermatology 1999;199:308-12
12. Ritchie HE, Brown-Woodman PD, Korabelnikoff A. Effect of co-administration of retinoids on rat embryo development in vitro. Birth Defects Res A, Clin Mol Teratol 2003;67:444-51
13. Xu J, Drew PD. 9-Cis-retinoic acid suppresses inflammatory responses of microglia and astrocytes. J Neuroimmunol 2006;171:135-44
14. Dermatitis. In: Marcovitch H, editor. Blacks Medical Dictionary. Lanham, MD: The Scarecrow Press, Inc.; 2006
15. Ruzicka T, Larsen FG, Galewicz, D, et al. Oral alitretinoin (9-cis-retinoic acid) therapy for chronic hand dermatitis in patients refractory to standard therapy: results of a randomized, double-blind, placebo-controlled, multicenter trial. Arch Dermatol 2004;140:1453-9
16. Rongioletti F, Zaccaria E, Viglizzo G. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience. Br J Dermatol 2006;155:856-7
17. Bodsworth NJ, Bloch M, Bower M, et al. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel 0.1% in cutaneous AIDS-related Kaposi's sarcoma, Am J Clin Dermatol 2001;2:77-87
18. Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group. J Acquir Immune Defic Syndr 1999;22:235-46
19. Bodsworth N. Topical 9-cis-retinoic acid (Panretin) gel as treatment of cutaneous AIDS-related Kaposi's sarcoma: interim results of an international, placebo-controlled trial (ALRT 1057-503) [Abstract 618/ 22277]. International Partretin KS Study Group. Int Conf AIDS 1998;12:317
20. Ligand Pharmaceuticals. Panretin® (alitretinoin) prescribing information; 2006
21. Aboulafia DM, Norris D, Henry D, et al. 9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: results of a phase 2 multicenter clinical trial. Arch Dermatol 2003;139:178-86
22. Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS 2002; 16:421-9
23. Baumann L, Vujevich J, Halem M, et al. Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis 2005;76:69-73
24. Maloney DM, Schmidt JD, Duvic M. Alitretinoin gel to treat pyogenic granuloma. J Am Acad Dermatol 2002;47:969-70
25. Bassiri-Tehrani S, Ba BA, Cohen DE. Treatment of cutaneous T-cell lymphoma with alitretinoin gel. Int J Dermatol 2002;41:104-6
26. Duvic M, Friedman-Kien AE, Galpin J, et al. Phase I/II clinical trial supports safety and efficacy of ALRT 1057 topical retinoid gel for Kaposi's sarcoma [Abstract]. International Conference on AIDS 1996;11:27
27. Miller VA, Rigas JR, Benedetti FM, et al. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin Cancer Res 1996;2:471-5